Johnson & Johnson, US4781601046

Johnson & Johnson stock gains on MONARCH QUEST 3 clearance

Published on 08/17/2026 at 17:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock is trading near $260 as fresh regulatory clearance for MONARCH QUEST 3 adds a new catalyst to a year that already includes higher 2026 guidance and a stronger dividend.

Modern hospital operating room with robotic surgical arms positioned above a draped patient, surgeons in blue sterile gowns monitoring vital-sign and anatomy screens, bright overhead surgical lighting, stainless steel instrument trays in the foreground
Johnson und US4781601046 zeigen modernen Krankenhaus OP mit Robotik Chirurgie und medizinischen Bildschirmen, Illustration mit AI erstellt.

Johnson & Johnson (US4781601046) stock was quoted at $260.61 on August 17, 2026, after a 0.10% move in one live market snapshot, while the 12-month range stood at $274.90 to $173.33 and market cap at $627.41 billion. MarketScreener's report on MONARCH QUEST 3 said Johnson & Johnson announced U.S. 510(k) clearance for the MONARCH Platform update on August 17, 2026.

Regulatory clearance lands

The latest product update adds another data point to a stock that already changed hands at $259.73 bid and $259.98 ask at 2:40 p.m. EDT on August 17, 2026. A separate market snapshot put the opening print at $260.44 and the current dividend yield at 2.06%, keeping the shares anchored in a narrow band around the $260 level.

For investors, the bigger backdrop still comes from the second quarter of 2026, when Johnson & Johnson reported $25.31 billion in revenue and $2.90 in EPS, both above consensus in the cited coverage. Revenue rose 6.6% year over year, while the full-year 2026 EPS guide stayed at $11.60 to $11.75.

Guidance still matters

The guidance band implies management is still aiming for adjusted earnings growth in 2026, and the consensus target price quoted in the same market data set was $268.22. That leaves the stock trading below the average target even after its 12-month high of $274.90 and a 1st Jan change of 25.57% in the cited real-time snapshot.

Market positioning also remains part of the story. One filing-based market note said institutional investors collectively own 69.55% of the stock, while another cited 64 consecutive years of dividend increases and a quarterly payout of $1.34 per share.

MONARCH in brief

MONARCH QUEST 3 is a software update for the MONARCH Platform, a robotically assisted bronchoscopy system used in early lung-cancer procedures. The release describes AI-powered nodule segmentation and a new 3D Compass overlay as part of the update.

Shares and yield

Johnson & Johnson shares remain tied to income as much as growth, with a cited annualized dividend of $5.36 per share and a yield of 2.06% in the latest market snapshot. The stock was last quoted at $260.61 in the same session.

Fact box

Company: Johnson & Johnson
ISIN: US4781601046
Ticker: JNJ
Exchange: NYSE
Sector / Industry: Healthcare / Pharmaceuticals
Index membership: Dow Jones Industrial Average
Market cap: $627.41 billion
Price: $260.61
Price as of: August 17, 2026, 9:56 a.m. EDT

Disclaimer...

en | US4781601046 | JOHNSON & JOHNSON | boerse | 69959781 | bgmi